Plain-English translation of NCT04330729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is exploring whether (a common blood thinner, also known as aspirin) can help prevent blood clots in people with severe kidney disease who are being treated with a medication called darbepoetin alfa. The researchers want to use modern tests to measure how this medication affects your blood platelets — the cells that form clots — to see if it can reduce the risk of clots without causing harm.
Medications like darbepoetin alfa, which help people with kidney disease make more red blood cells, have a known side effect: they increase the risk of dangerous blood clots in the brain, heart, and elsewhere. The researchers hope that this medication might reduce that risk by changing how blood platelets behave, which could help patients receive safer treatment.
You likely qualify if…
You likely don't qualify if…
You will first stop any current blood-boosting medications for 4–6 weeks while the researchers take baseline blood samples. Then you'll restart the blood-boosting medication (darbepoetin alfa) for 4 weeks, followed by 4 more weeks of the same medication plus a daily 75 mg tablet of . Throughout this 12-week period, you'll have regular blood tests to measure how your blood cells respond and to adjust doses if needed. The study lasts about 3 months total.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark